Department of Hematology, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang, China.
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
J Immunother Cancer. 2023 Nov 27;11(11):e007790. doi: 10.1136/jitc-2023-007790.
Chimeric antigen receptor (CAR) T cell therapy is an advanced and effective immunotherapy for relapsed or refractory B-cell malignancies. High expansion of CAR T cells in vivo and durable antitumor activity indicate a persistent therapeutic response. However, this treatment is linked to a high frequency of adverse events, such as cytokine release syndrome (CRS), which affects its efficacy and can even be life-threatening. At present, a variety of markers associated with clinical response and treatment toxicity after CAR T cells infusion have been reported. Although these biomarkers can act as effective indicators reflecting CAR T cells expansion as well as CRS, they fail to predict the expansion rate of CAR T cells. Hence, further investigation is urgent to find a new biomarker to fill this void.
We analyzed the association between the absolute neutrophil count (ANC) and CAR expansion and CRS in 45 patients with B-cell malignancies from two clinical trials. We proposed that ANC could be a practical biomarker for CAR T cells expansion and CRS, and conducted a feasibility analysis on its predictive ability.
In this study, 17 B-cell hematological malignancy patients with anti-B-cell maturation antigen CAR-treated and 28 with CAR19/22 T-cell-treated were enrolled and divided into an ANC-absence group and an ANC-presence group. The results showed that ANC absence correlated positively with CAR expansion and the expansion rate. The ANC can be used as a predictive marker for CAR T cells expansion. Moreover, the patients with ANC absence experienced a more severe CRS, and ANC performed a predictive ability for CRS. In addition, the peak serum concentration of several cytokines involved in CRS was higher in patients with ANC absence.
Thus, we suggest ANC as an evaluative and predictive biomarker for CAR expansion and CRS during CAR T cell therapy, which can help to maximize clinical efficacy, reduce treatment-related toxicity and prolong survival.
嵌合抗原受体(CAR)T 细胞疗法是一种用于治疗复发或难治性 B 细胞恶性肿瘤的先进且有效的免疫疗法。CAR T 细胞在体内的高扩增和持久的抗肿瘤活性表明存在持续的治疗反应。然而,这种治疗与不良反应的高频率相关,例如细胞因子释放综合征(CRS),这会影响其疗效,甚至危及生命。目前,已经报道了多种与 CAR T 细胞输注后临床反应和治疗毒性相关的标志物。尽管这些生物标志物可以作为反映 CAR T 细胞扩增和 CRS 的有效指标,但它们无法预测 CAR T 细胞的扩增速度。因此,迫切需要进一步研究以寻找新的生物标志物来填补这一空白。
我们分析了来自两项临床试验的 45 名 B 细胞恶性肿瘤患者的绝对中性粒细胞计数(ANC)与 CAR 扩增和 CRS 之间的关系。我们提出 ANC 可能是 CAR T 细胞扩增和 CRS 的实用生物标志物,并对其预测能力进行了可行性分析。
本研究纳入了 17 名接受抗 B 细胞成熟抗原 CAR 治疗的 B 细胞血液恶性肿瘤患者和 28 名接受 CAR19/22 T 细胞治疗的患者,并将其分为 ANC 缺失组和 ANC 存在组。结果表明,ANC 缺失与 CAR 扩增及其扩增率呈正相关。ANC 可用作 CAR T 细胞扩增的预测标志物。此外,ANC 缺失的患者发生更严重的 CRS,ANC 对 CRS 具有预测能力。此外,ANC 缺失的患者中几种与 CRS 相关的细胞因子的血清峰值浓度更高。
因此,我们建议 ANC 作为 CAR T 细胞治疗过程中 CAR 扩增和 CRS 的评估和预测生物标志物,有助于最大限度地提高临床疗效,降低治疗相关毒性并延长生存时间。